Heat Biologics, Inc. (HTBX) Financial Analysis & Valuation | Quarter Chart
Heat Biologics, Inc. (HTBX)
HTBXPrice: $2.38
Fair Value: 🔒
🔒score
Heat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an ... more
Heat Biologics, Inc., an integrated biopharmaceutical company, engages in the development of immune ... more
Description
Shares
| Market Cap | $61.07M | Exchange | AMEX |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Jeffrey Wolf |
| IPO Date | 2013-07-24 | CAGR | 0.27% |
| Employees | 49 | Website | www.heatbio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
HTBX chart loading...
Fundamentals
Technicals
| Enterprise Value | $17535.08B | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | — |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $-1.15 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 837372511.38% | Gross Margin | 0.43% |
| Operating Margin | -6.12% | Profit Margin | -7.03% |
| ROE | -173.91% | ROA | -2.34% |
| ROCE | 29.7% | Current Ratio | 0.1 |
| Quick Ratio | 0.09 | Cash Ratio | 0.03 |
| Debt/Equity | -13.62 | Interest Coverage | -51.29 |
| Altman Z Score | -22.52 | Piotroski Score | 2 |